Investigation of the Effects of Dietary Nitrate and Sex on COVID-19 Vaccine Induced Vascular Dysfunction in Healthy Men and Women (DiNOVasc-COVID-19)
Launched by QUEEN MARY UNIVERSITY OF LONDON · May 14, 2021
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called DiNOVasc-COVID-19, is looking at how dietary nitrate might help protect blood vessels from damage related to COVID-19 vaccination. Researchers want to find out if there are differences in how men and women respond to the vaccine and if taking dietary nitrate can help reduce inflammation in the body after vaccination. The study has two parts: the first part examines whether men and women react differently to the vaccine, and the second part tests if nitrate supplements can increase certain substances in the blood that help protect blood vessels.
To participate in this study, you need to be a healthy adult aged 18 to 60 who has a scheduled COVID-19 vaccination. You must also be willing to sign a consent form to join the trial. Unfortunately, people with certain health conditions, recent infections, or those who have had prior COVID-19 vaccinations are not eligible. If you join, you can expect to have your vascular health assessed before and after your vaccination, and you'll receive either the dietary nitrate or a placebo (a harmless substance) to compare effects. This study is currently active but not recruiting new participants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Healthy volunteers with a booking for COVID-19 vaccination slot as per government guidelines
- • 2. Aged 18-60
- • 3. Volunteers who are willing to sign the consent form
- Exclusion Criteria:
- • 1. Aged \<18 or \>60 years
- • 2. Healthy subjects unwilling to consent
- • 3. Pregnant, or any possibility that a subject may be pregnant
- • 4. History of any serious illnesses, including recent infections or trauma
- • 5. Subjects taking systemic medication (other than the oral contraceptive pill)
- • 6. Subjects with self-reported use of mouthwash or tongue scrapes
- • 7. Subjects with recent (2 weeks) or current antibiotic use
- • 8. Subjects with a history, or recent treatment of (within last 3 months) any oral condition (excluding caries), including gingivitis, periodontitis and halitosis
- • 9. Subjects with a history of COVID-19 vaccination
- • 10. Subjects with any history of a blood-borne infectious
About Queen Mary University Of London
Queen Mary University of London is a prestigious research-intensive institution recognized for its commitment to advancing medical science and improving health outcomes. As a leading sponsor of clinical trials, the university harnesses its academic excellence and innovative research capabilities to explore groundbreaking treatments and therapies across various medical disciplines. With a focus on collaboration, the institution engages with a diverse network of clinicians, researchers, and industry partners to ensure rigorous study design, ethical conduct, and the translation of research findings into clinical practice. Queen Mary University of London is dedicated to contributing to the global body of knowledge in healthcare through high-quality clinical research that prioritizes patient safety and welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials